#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=The rapid development of large-scale pharmaceutical manufacturing has contributed to increased concentrations of contaminants present in wastewater and surface waters .
2-1	16-19	The	event[2]	new[2]	_	_
2-2	20-25	rapid	event[2]	new[2]	_	_
2-3	26-37	development	event[2]	new[2]	_	_
2-4	38-40	of	event[2]	new[2]	_	_
2-5	41-52	large-scale	event[2]|abstract[3]	new[2]|new[3]	coref	3-8[0_3]
2-6	53-67	pharmaceutical	event[2]|abstract[3]	new[2]|new[3]	_	_
2-7	68-81	manufacturing	event[2]|abstract[3]	new[2]|new[3]	_	_
2-8	82-85	has	_	_	_	_
2-9	86-97	contributed	_	_	_	_
2-10	98-100	to	_	_	_	_
2-11	101-110	increased	substance[4]	new[4]	_	_
2-12	111-125	concentrations	substance[4]	new[4]	_	_
2-13	126-128	of	substance[4]	new[4]	_	_
2-14	129-141	contaminants	substance[4]|substance[5]	new[4]|new[5]	_	_
2-15	142-149	present	substance[4]|substance[5]	new[4]|new[5]	_	_
2-16	150-152	in	substance[4]|substance[5]	new[4]|new[5]	_	_
2-17	153-163	wastewater	substance[4]|substance[5]|substance|substance[7]	new[4]|new[5]|new|new[7]	coref|coref	5-19|10-18[77_7]
2-18	164-167	and	substance[4]|substance[5]|substance[7]	new[4]|new[5]|new[7]	_	_
2-19	168-175	surface	substance[4]|substance[5]|substance[7]|place|substance[9]	new[4]|new[5]|new[7]|new|new[9]	_	_
2-20	176-182	waters	substance[4]|substance[5]|substance[7]|substance[9]	new[4]|new[5]|new[7]|new[9]	_	_
2-21	183-184	.	_	_	_	_

#Text=Pharmaceutical wastewaters are produced during the drug manufacturing processes ( i.e. , fermentation , extraction , chemical synthesis , formulation , packaging and washing of solid cake and equipment ) .
3-1	185-199	Pharmaceutical	substance[10]	new[10]	_	_
3-2	200-211	wastewaters	substance[10]	new[10]	_	_
3-3	212-215	are	_	_	_	_
3-4	216-224	produced	_	_	_	_
3-5	225-231	during	_	_	_	_
3-6	232-235	the	abstract[13]	new[13]	appos	3-11[15_13]
3-7	236-240	drug	substance|abstract[13]	new|new[13]	_	_
3-8	241-254	manufacturing	abstract|abstract[13]	giv|new[13]	coref	6-4[43_0]
3-9	255-264	processes	abstract[13]	new[13]	_	_
3-10	265-266	(	_	_	_	_
3-11	267-271	i.e.	substance[14]|abstract[15]	new[14]|giv[15]	appos	3-17[17_15]
3-12	272-273	,	substance[14]|abstract[15]	new[14]|giv[15]	_	_
3-13	274-286	fermentation	substance[14]|abstract[15]	new[14]|giv[15]	_	_
3-14	287-288	,	abstract[15]	giv[15]	_	_
3-15	289-299	extraction	abstract[15]|event	giv[15]|new	_	_
3-16	300-301	,	abstract[15]	giv[15]	_	_
3-17	302-310	chemical	abstract[15]|abstract[17]	giv[15]|giv[17]	appos	3-20[0_17]
3-18	311-320	synthesis	abstract[15]|abstract[17]	giv[15]|giv[17]	_	_
3-19	321-322	,	abstract[15]	giv[15]	_	_
3-20	323-334	formulation	abstract[15]|abstract	giv[15]|giv	appos	3-22
3-21	335-336	,	abstract[15]	giv[15]	_	_
3-22	337-346	packaging	abstract[15]|abstract	giv[15]|giv	appos	3-24[20_0]
3-23	347-350	and	abstract[15]	giv[15]	_	_
3-24	351-358	washing	abstract[15]|abstract[20]	giv[15]|giv[20]	coref	15-12[103_20]
3-25	359-361	of	abstract[15]|abstract[20]	giv[15]|giv[20]	_	_
3-26	362-367	solid	abstract[15]|abstract[20]|object[21]	giv[15]|giv[20]|new[21]	_	_
3-27	368-372	cake	abstract[15]|abstract[20]|object[21]	giv[15]|giv[20]|new[21]	_	_
3-28	373-376	and	abstract[15]|abstract[20]	giv[15]|giv[20]	_	_
3-29	377-386	equipment	abstract[15]|abstract[20]|object	giv[15]|giv[20]|new	_	_
3-30	387-388	)	_	_	_	_
3-31	389-390	.	_	_	_	_

#Text=Hence , the main pollution source of these pharmaceutical compounds in the environment is through industrial process water discharge .
4-1	391-396	Hence	_	_	_	_
4-2	397-398	,	_	_	_	_
4-3	399-402	the	abstract[24]	new[24]	_	_
4-4	403-407	main	abstract[24]	new[24]	_	_
4-5	408-417	pollution	abstract|abstract[24]	new|new[24]	_	_
4-6	418-424	source	abstract[24]	new[24]	_	_
4-7	425-427	of	abstract[24]	new[24]	_	_
4-8	428-433	these	abstract[24]|substance[25]	new[24]|new[25]	_	_
4-9	434-448	pharmaceutical	abstract[24]|substance[25]	new[24]|new[25]	_	_
4-10	449-458	compounds	abstract[24]|substance[25]	new[24]|new[25]	_	_
4-11	459-461	in	abstract[24]	new[24]	_	_
4-12	462-465	the	abstract[24]|place[26]	new[24]|new[26]	_	_
4-13	466-477	environment	abstract[24]|place[26]	new[24]|new[26]	_	_
4-14	478-480	is	_	_	_	_
4-15	481-488	through	_	_	_	_
4-16	489-499	industrial	event[29]	new[29]	_	_
4-17	500-507	process	event|substance[28]|event[29]	new|new[28]|new[29]	coref	13-12
4-18	508-513	water	substance[28]|event[29]	new[28]|new[29]	_	_
4-19	514-523	discharge	event[29]	new[29]	_	_
4-20	524-525	.	_	_	_	_

#Text=Several studies have shown that pharmaceutical drugs ( and their derived metabolites ) are found in effluents of wastewater treatment plants ( WWTPs ) and their removal is very inefficient .
5-1	526-533	Several	abstract[30]	new[30]	_	_
5-2	534-541	studies	abstract[30]	new[30]	_	_
5-3	542-546	have	_	_	_	_
5-4	547-552	shown	_	_	_	_
5-5	553-557	that	_	_	_	_
5-6	558-572	pharmaceutical	substance[31]|object[32]	new[31]|new[32]	ana|coref	5-10[0_32]|6-7[44_31]
5-7	573-578	drugs	substance[31]|object[32]	new[31]|new[32]	_	_
5-8	579-580	(	object[32]	new[32]	_	_
5-9	581-584	and	object[32]	new[32]	_	_
5-10	585-590	their	object[32]|object|substance[34]	new[32]|giv|new[34]	ana	5-26
5-11	591-598	derived	object[32]|substance[34]	new[32]|new[34]	_	_
5-12	599-610	metabolites	object[32]|substance[34]	new[32]|new[34]	_	_
5-13	611-612	)	object[32]	new[32]	_	_
5-14	613-616	are	_	_	_	_
5-15	617-622	found	_	_	_	_
5-16	623-625	in	_	_	_	_
5-17	626-635	effluents	substance[35]	new[35]	_	_
5-18	636-638	of	substance[35]	new[35]	_	_
5-19	639-649	wastewater	substance[35]|substance|place[38]	new[35]|giv|new[38]	coref|coref	6-1[42_0]|9-14[70_38]
5-20	650-659	treatment	substance[35]|abstract|place[38]	new[35]|new|new[38]	coref	9-16
5-21	660-666	plants	substance[35]|place[38]	new[35]|new[38]	_	_
5-22	667-668	(	_	_	_	_
5-23	669-674	WWTPs	organization	new	_	_
5-24	675-676	)	_	_	_	_
5-25	677-680	and	_	_	_	_
5-26	681-686	their	object|event[41]	giv|new[41]	coref	15-17[104_41]
5-27	687-694	removal	event[41]	new[41]	_	_
5-28	695-697	is	_	_	_	_
5-29	698-702	very	_	_	_	_
5-30	703-714	inefficient	_	_	_	_
5-31	715-716	.	_	_	_	_

#Text=Wastewater originating during the manufacturing of antidiabetic drugs is also an important environmental challenge due to the high production volume .
6-1	717-727	Wastewater	substance[42]	giv[42]	coref	6-11[45_42]
6-2	728-739	originating	substance[42]	giv[42]	_	_
6-3	740-746	during	substance[42]	giv[42]	_	_
6-4	747-750	the	substance[42]|abstract[43]	giv[42]|giv[43]	_	_
6-5	751-764	manufacturing	substance[42]|abstract[43]	giv[42]|giv[43]	_	_
6-6	765-767	of	substance[42]|abstract[43]	giv[42]|giv[43]	_	_
6-7	768-780	antidiabetic	substance[42]|abstract[43]|substance[44]	giv[42]|giv[43]|giv[44]	coref	7-15[52_44]
6-8	781-786	drugs	substance[42]|abstract[43]|substance[44]	giv[42]|giv[43]|giv[44]	_	_
6-9	787-789	is	_	_	_	_
6-10	790-794	also	_	_	_	_
6-11	795-797	an	substance[45]	giv[45]	coref	7-18[0_45]
6-12	798-807	important	substance[45]	giv[45]	_	_
6-13	808-821	environmental	substance[45]	giv[45]	_	_
6-14	822-831	challenge	substance[45]	giv[45]	_	_
6-15	832-835	due	substance[45]	giv[45]	_	_
6-16	836-838	to	substance[45]	giv[45]	_	_
6-17	839-842	the	substance[45]|abstract[47]	giv[45]|new[47]	_	_
6-18	843-847	high	substance[45]|abstract[47]	giv[45]|new[47]	_	_
6-19	848-858	production	substance[45]|abstract|abstract[47]	giv[45]|new|new[47]	_	_
6-20	859-865	volume	substance[45]|abstract[47]	giv[45]|new[47]	_	_
6-21	866-867	.	_	_	_	_

#Text=Several research papers have reported the occurrence , degradability , and environmental impact of antidiabetic drugs in wastewater , and substantial efforts to achieve environmental improvements in line with regulations and legislation have been implemented .
7-1	868-875	Several	abstract[48]	new[48]	_	_
7-2	876-884	research	abstract[48]	new[48]	_	_
7-3	885-891	papers	abstract[48]	new[48]	_	_
7-4	892-896	have	_	_	_	_
7-5	897-905	reported	_	_	_	_
7-6	906-909	the	event[49]	new[49]	_	_
7-7	910-920	occurrence	event[49]	new[49]	_	_
7-8	921-922	,	_	_	_	_
7-9	923-936	degradability	abstract	new	_	_
7-10	937-938	,	_	_	_	_
7-11	939-942	and	_	_	_	_
7-12	943-956	environmental	abstract[51]	new[51]	_	_
7-13	957-963	impact	abstract[51]	new[51]	_	_
7-14	964-966	of	abstract[51]	new[51]	_	_
7-15	967-979	antidiabetic	abstract[51]|substance[52]	new[51]|giv[52]	coref	8-8[61_52]
7-16	980-985	drugs	abstract[51]|substance[52]	new[51]|giv[52]	_	_
7-17	986-988	in	abstract[51]	new[51]	_	_
7-18	989-999	wastewater	abstract[51]|substance	new[51]|giv	coref	9-15
7-19	1000-1001	,	_	_	_	_
7-20	1002-1005	and	_	_	_	_
7-21	1006-1017	substantial	event[54]	new[54]	_	_
7-22	1018-1025	efforts	event[54]	new[54]	_	_
7-23	1026-1028	to	event[54]	new[54]	_	_
7-24	1029-1036	achieve	event[54]	new[54]	_	_
7-25	1037-1050	environmental	event[54]|abstract[55]	new[54]|new[55]	_	_
7-26	1051-1063	improvements	event[54]|abstract[55]	new[54]|new[55]	_	_
7-27	1064-1066	in	event[54]|abstract[55]	new[54]|new[55]	_	_
7-28	1067-1071	line	event[54]|abstract[55]	new[54]|new[55]	_	_
7-29	1072-1076	with	event[54]|abstract[55]	new[54]|new[55]	_	_
7-30	1077-1088	regulations	event[54]|abstract[55]|abstract	new[54]|new[55]|new	_	_
7-31	1089-1092	and	event[54]|abstract[55]	new[54]|new[55]	_	_
7-32	1093-1104	legislation	event[54]|abstract[55]|abstract	new[54]|new[55]|new	_	_
7-33	1105-1109	have	_	_	_	_
7-34	1110-1114	been	_	_	_	_
7-35	1115-1126	implemented	_	_	_	_
7-36	1127-1128	.	_	_	_	_

#Text=Metformin ( C4H11N5 ) is one of the most prescribed and widely used antidiabetic drugs worldwide , since a significant portion of the population suffers from diabetes .
8-1	1129-1138	Metformin	substance	new	appos	8-3
8-2	1139-1140	(	_	_	_	_
8-3	1141-1148	C4H11N5	substance	giv	coref	9-12
8-4	1149-1150	)	_	_	_	_
8-5	1151-1153	is	_	_	_	_
8-6	1154-1157	one	person[60]	new[60]	_	_
8-7	1158-1160	of	person[60]	new[60]	_	_
8-8	1161-1164	the	person[60]|substance[61]	new[60]|giv[61]	_	_
8-9	1165-1169	most	person[60]|substance[61]	new[60]|giv[61]	_	_
8-10	1170-1180	prescribed	person[60]|substance[61]	new[60]|giv[61]	_	_
8-11	1181-1184	and	person[60]|substance[61]	new[60]|giv[61]	_	_
8-12	1185-1191	widely	person[60]|substance[61]	new[60]|giv[61]	_	_
8-13	1192-1196	used	person[60]|substance[61]	new[60]|giv[61]	_	_
8-14	1197-1209	antidiabetic	person[60]|substance[61]	new[60]|giv[61]	_	_
8-15	1210-1215	drugs	person[60]|substance[61]	new[60]|giv[61]	_	_
8-16	1216-1225	worldwide	person[60]|substance[61]	new[60]|giv[61]	_	_
8-17	1226-1227	,	_	_	_	_
8-18	1228-1233	since	_	_	_	_
8-19	1234-1235	a	person[62]	new[62]	_	_
8-20	1236-1247	significant	person[62]	new[62]	_	_
8-21	1248-1255	portion	person[62]	new[62]	_	_
8-22	1256-1258	of	person[62]	new[62]	_	_
8-23	1259-1262	the	person[62]|person[63]	new[62]|new[63]	_	_
8-24	1263-1273	population	person[62]|person[63]	new[62]|new[63]	_	_
8-25	1274-1281	suffers	_	_	_	_
8-26	1282-1286	from	_	_	_	_
8-27	1287-1295	diabetes	abstract	new	_	_
8-28	1296-1297	.	_	_	_	_

#Text=Recent reports have indicated that there are also high concentrations of metformin in domestic wastewater treatment plants ’ influent .
9-1	1298-1304	Recent	abstract[65]	new[65]	_	_
9-2	1305-1312	reports	abstract[65]	new[65]	_	_
9-3	1313-1317	have	_	_	_	_
9-4	1318-1327	indicated	_	_	_	_
9-5	1328-1332	that	_	_	_	_
9-6	1333-1338	there	_	_	_	_
9-7	1339-1342	are	_	_	_	_
9-8	1343-1347	also	_	_	_	_
9-9	1348-1352	high	substance[66]	new[66]	_	_
9-10	1353-1367	concentrations	substance[66]	new[66]	_	_
9-11	1368-1370	of	substance[66]	new[66]	_	_
9-12	1371-1380	metformin	substance[66]|substance	new[66]|giv	ana	10-4
9-13	1381-1383	in	_	_	_	_
9-14	1384-1392	domestic	place[70]|substance[71]	giv[70]|new[71]	ana|coref	10-1[0_71]|14-21[100_70]
9-15	1393-1403	wastewater	substance|place[70]|substance[71]	giv|giv[70]|new[71]	coref	10-18
9-16	1404-1413	treatment	abstract|place[70]|substance[71]	giv|giv[70]|new[71]	coref	12-7[86_0]
9-17	1414-1420	plants	place[70]|substance[71]	giv[70]|new[71]	_	_
9-18	1421-1422	’	place[70]|substance[71]	giv[70]|new[71]	_	_
9-19	1423-1431	influent	substance[71]	new[71]	_	_
9-20	1432-1433	.	_	_	_	_

#Text=This is because it is excreted un-metabolized from the human body in urine and ends up in wastewater and aquatic environments .
10-1	1434-1438	This	substance	giv	_	_
10-2	1439-1441	is	_	_	_	_
10-3	1442-1449	because	_	_	_	_
10-4	1450-1452	it	substance	giv	coref	11-1
10-5	1453-1455	is	_	_	_	_
10-6	1456-1464	excreted	_	_	_	_
10-7	1465-1479	un-metabolized	_	_	_	_
10-8	1480-1484	from	_	_	_	_
10-9	1485-1488	the	object[74]	new[74]	_	_
10-10	1489-1494	human	object[74]	new[74]	_	_
10-11	1495-1499	body	object[74]	new[74]	_	_
10-12	1500-1502	in	_	_	_	_
10-13	1503-1508	urine	substance	new	_	_
10-14	1509-1512	and	_	_	_	_
10-15	1513-1517	ends	_	_	_	_
10-16	1518-1520	up	_	_	_	_
10-17	1521-1523	in	_	_	_	_
10-18	1524-1534	wastewater	substance|substance[77]	giv|giv[77]	coref	11-11[82_0]
10-19	1535-1538	and	substance[77]	giv[77]	_	_
10-20	1539-1546	aquatic	substance[77]|place[78]	giv[77]|new[78]	_	_
10-21	1547-1559	environments	substance[77]|place[78]	giv[77]|new[78]	_	_
10-22	1560-1561	.	_	_	_	_

#Text=Metformin is the pharmaceutical compound with the highest concentration in domestic wastewater ( i.e. , 64 – 98 µg/L ) .
11-1	1562-1571	Metformin	substance	giv	coref	11-3[80_0]
11-2	1572-1574	is	_	_	_	_
11-3	1575-1578	the	substance[80]	giv[80]	coref	14-1[0_80]
11-4	1579-1593	pharmaceutical	substance[80]	giv[80]	_	_
11-5	1594-1602	compound	substance[80]	giv[80]	_	_
11-6	1603-1607	with	substance[80]	giv[80]	_	_
11-7	1608-1611	the	substance[80]|abstract[81]	giv[80]|new[81]	_	_
11-8	1612-1619	highest	substance[80]|abstract[81]	giv[80]|new[81]	_	_
11-9	1620-1633	concentration	substance[80]|abstract[81]	giv[80]|new[81]	_	_
11-10	1634-1636	in	substance[80]|abstract[81]	giv[80]|new[81]	_	_
11-11	1637-1645	domestic	substance[80]|abstract[81]|substance[82]	giv[80]|new[81]|giv[82]	coref	12-7[0_82]
11-12	1646-1656	wastewater	substance[80]|abstract[81]|substance[82]	giv[80]|new[81]|giv[82]	_	_
11-13	1657-1658	(	_	_	_	_
11-14	1659-1663	i.e.	abstract[83]	new[83]	_	_
11-15	1664-1665	,	abstract[83]	new[83]	_	_
11-16	1666-1668	64	abstract[83]	new[83]	_	_
11-17	1669-1670	–	abstract[83]	new[83]	_	_
11-18	1671-1673	98	abstract[83]	new[83]	_	_
11-19	1674-1678	µg/L	abstract[83]	new[83]	_	_
11-20	1679-1680	)	_	_	_	_
11-21	1681-1682	.	_	_	_	_

#Text=This study is therefore relevant for wastewater treatment in general , even though it is focused on metformin-containing industrial wastewater .
12-1	1683-1687	This	abstract[84]	new[84]	coref	16-5[108_84]
12-2	1688-1693	study	abstract[84]	new[84]	_	_
12-3	1694-1696	is	_	_	_	_
12-4	1697-1706	therefore	_	_	_	_
12-5	1707-1715	relevant	_	_	_	_
12-6	1716-1719	for	_	_	_	_
12-7	1720-1730	wastewater	substance|abstract[86]	giv|giv[86]	ana|coref	12-14[0_86]|12-18[89_0]
12-8	1731-1740	treatment	abstract[86]	giv[86]	_	_
12-9	1741-1743	in	abstract[86]	giv[86]	_	_
12-10	1744-1751	general	abstract[86]	giv[86]	_	_
12-11	1752-1753	,	_	_	_	_
12-12	1754-1758	even	_	_	_	_
12-13	1759-1765	though	_	_	_	_
12-14	1766-1768	it	abstract	giv	coref	14-22
12-15	1769-1771	is	_	_	_	_
12-16	1772-1779	focused	_	_	_	_
12-17	1780-1782	on	_	_	_	_
12-18	1783-1803	metformin-containing	substance|substance[89]	new|giv[89]	coref	13-1[90_89]
12-19	1804-1814	industrial	substance[89]	giv[89]	_	_
12-20	1815-1825	wastewater	substance[89]	giv[89]	_	_
12-21	1826-1827	.	_	_	_	_

#Text=Pharmaceutical wastewater has traditionally been treated using conventional physico-chemical and biological process methods .
13-1	1828-1842	Pharmaceutical	substance[90]	giv[90]	coref	14-21[0_90]
13-2	1843-1853	wastewater	substance[90]	giv[90]	_	_
13-3	1854-1857	has	_	_	_	_
13-4	1858-1871	traditionally	_	_	_	_
13-5	1872-1876	been	_	_	_	_
13-6	1877-1884	treated	_	_	_	_
13-7	1885-1890	using	_	_	_	_
13-8	1891-1903	conventional	abstract[92]	new[92]	_	_
13-9	1904-1920	physico-chemical	abstract[92]	new[92]	_	_
13-10	1921-1924	and	abstract[92]	new[92]	_	_
13-11	1925-1935	biological	abstract[92]	new[92]	_	_
13-12	1936-1943	process	event|abstract[92]	giv|new[92]	coref	21-1[141_0]
13-13	1944-1951	methods	abstract[92]	new[92]	_	_
13-14	1952-1953	.	_	_	_	_

#Text=Metformin can be aerobically degraded to guanylurea ( C2H6N4O ) — a metabolite that is stable against further biodegradation in wastewater treatment plants .
14-1	1954-1963	Metformin	substance	giv	coref	15-21
14-2	1964-1967	can	_	_	_	_
14-3	1968-1970	be	_	_	_	_
14-4	1971-1982	aerobically	_	_	_	_
14-5	1983-1991	degraded	_	_	_	_
14-6	1992-1994	to	_	_	_	_
14-7	1995-2005	guanylurea	substance	new	appos	14-9
14-8	2006-2007	(	_	_	_	_
14-9	2008-2015	C2H6N4O	substance	giv	appos	14-12[96_0]
14-10	2016-2017	)	_	_	_	_
14-11	2018-2019	—	_	_	_	_
14-12	2020-2021	a	substance[96]	giv[96]	_	_
14-13	2022-2032	metabolite	substance[96]	giv[96]	_	_
14-14	2033-2037	that	substance[96]	giv[96]	_	_
14-15	2038-2040	is	substance[96]	giv[96]	_	_
14-16	2041-2047	stable	substance[96]	giv[96]	_	_
14-17	2048-2055	against	substance[96]	giv[96]	_	_
14-18	2056-2063	further	substance[96]|substance[97]	giv[96]|new[97]	ana	15-3[0_97]
14-19	2064-2078	biodegradation	substance[96]|substance[97]	giv[96]|new[97]	_	_
14-20	2079-2081	in	substance[96]|substance[97]	giv[96]|new[97]	_	_
14-21	2082-2092	wastewater	substance[96]|substance[97]|substance|place[100]	giv[96]|new[97]|giv|giv[100]	coref	23-1
14-22	2093-2102	treatment	substance[96]|substance[97]|abstract|place[100]	giv[96]|new[97]|giv|giv[100]	coref	25-8[157_0]
14-23	2103-2109	plants	substance[96]|substance[97]|place[100]	giv[96]|new[97]|giv[100]	_	_
14-24	2110-2111	.	_	_	_	_

#Text=However , it appears to be a novel idea to integrate anaerobic and aerobic processes for the efficient removal of metformin and other pharmaceutical constituents .
15-1	2112-2119	However	_	_	_	_
15-2	2120-2121	,	_	_	_	_
15-3	2122-2124	it	substance	giv	_	_
15-4	2125-2132	appears	_	_	_	_
15-5	2133-2135	to	_	_	_	_
15-6	2136-2138	be	_	_	_	_
15-7	2139-2140	a	abstract[102]	new[102]	_	_
15-8	2141-2146	novel	abstract[102]	new[102]	_	_
15-9	2147-2151	idea	abstract[102]	new[102]	_	_
15-10	2152-2154	to	abstract[102]	new[102]	_	_
15-11	2155-2164	integrate	abstract[102]	new[102]	_	_
15-12	2165-2174	anaerobic	abstract[102]|abstract[103]	new[102]|giv[103]	coref	22-8[148_103]
15-13	2175-2178	and	abstract[102]|abstract[103]	new[102]|giv[103]	_	_
15-14	2179-2186	aerobic	abstract[102]|abstract[103]	new[102]|giv[103]	_	_
15-15	2187-2196	processes	abstract[102]|abstract[103]	new[102]|giv[103]	_	_
15-16	2197-2200	for	abstract[102]	new[102]	_	_
15-17	2201-2204	the	abstract[102]|event[104]	new[102]|giv[104]	coref	29-45[0_104]
15-18	2205-2214	efficient	abstract[102]|event[104]	new[102]|giv[104]	_	_
15-19	2215-2222	removal	abstract[102]|event[104]	new[102]|giv[104]	_	_
15-20	2223-2225	of	abstract[102]|event[104]	new[102]|giv[104]	_	_
15-21	2226-2235	metformin	abstract[102]|event[104]|substance	new[102]|giv[104]|giv	coref	29-36
15-22	2236-2239	and	abstract[102]|event[104]	new[102]|giv[104]	_	_
15-23	2240-2245	other	abstract[102]|event[104]|substance[106]	new[102]|giv[104]|new[106]	coref	21-6[142_106]
15-24	2246-2260	pharmaceutical	abstract[102]|event[104]|substance[106]	new[102]|giv[104]|new[106]	_	_
15-25	2261-2273	constituents	abstract[102]|event[104]|substance[106]	new[102]|giv[104]|new[106]	_	_
15-26	2274-2275	.	_	_	_	_

#Text=The basic hypothesis of this study is that anaerobic granular sludge and aerobic biofilms supported by a hybrid vertical anaerobic biofilm ( HyVAB® ) reactor design (
16-1	2276-2279	The	abstract[107]	new[107]	_	_
16-2	2280-2285	basic	abstract[107]	new[107]	_	_
16-3	2286-2296	hypothesis	abstract[107]	new[107]	_	_
16-4	2297-2299	of	abstract[107]	new[107]	_	_
16-5	2300-2304	this	abstract[107]|abstract[108]	new[107]|giv[108]	coref	29-2[183_108]
16-6	2305-2310	study	abstract[107]|abstract[108]	new[107]|giv[108]	_	_
16-7	2311-2313	is	_	_	_	_
16-8	2314-2318	that	_	_	_	_
16-9	2319-2328	anaerobic	substance[109]	new[109]	_	_
16-10	2329-2337	granular	substance[109]	new[109]	_	_
16-11	2338-2344	sludge	substance[109]	new[109]	_	_
16-12	2345-2348	and	_	_	_	_
16-13	2349-2356	aerobic	abstract[110]	new[110]	coref	16-17[114_110]
16-14	2357-2365	biofilms	abstract[110]	new[110]	_	_
16-15	2366-2375	supported	_	_	_	_
16-16	2376-2378	by	_	_	_	_
16-17	2379-2380	a	abstract[114]	giv[114]	_	_
16-18	2381-2387	hybrid	abstract[114]	giv[114]	_	_
16-19	2388-2396	vertical	abstract[111]|abstract[114]	new[111]|giv[114]	appos	16-23[0_111]
16-20	2397-2406	anaerobic	abstract[111]|abstract[114]	new[111]|giv[114]	_	_
16-21	2407-2414	biofilm	abstract[111]|abstract[114]	new[111]|giv[114]	_	_
16-22	2415-2416	(	abstract[114]	giv[114]	_	_
16-23	2417-2423	HyVAB®	abstract|abstract[114]	giv|giv[114]	coref	22-1
16-24	2424-2425	)	abstract[114]	giv[114]	_	_
16-25	2426-2433	reactor	object|abstract[114]	new|giv[114]	_	_
16-26	2434-2440	design	abstract[114]	giv[114]	_	_
16-27	2441-2442	(	_	_	_	_

#Text=Figure 1
17-1	2443-2449	Figure	abstract[115]	new[115]	_	_
17-2	2450-2451	1	abstract[115]	new[115]	_	_

#Text=) are the most robust combined niches for microorganisms to treat inhibitory substances , since microbial aggregates protect the microorganisms against such substances as they are delivered slowly by diffusion from the liquid phase .
18-1	2452-2453	)	_	_	_	_
18-2	2454-2457	are	_	_	_	_
18-3	2458-2461	the	place[116]	new[116]	ana	18-25[0_116]
18-4	2462-2466	most	place[116]	new[116]	_	_
18-5	2467-2473	robust	place[116]	new[116]	_	_
18-6	2474-2482	combined	place[116]	new[116]	_	_
18-7	2483-2489	niches	place[116]	new[116]	_	_
18-8	2490-2493	for	place[116]	new[116]	_	_
18-9	2494-2508	microorganisms	place[116]|abstract[117]	new[116]|new[117]	coref	18-19[120_117]
18-10	2509-2511	to	place[116]|abstract[117]	new[116]|new[117]	_	_
18-11	2512-2517	treat	place[116]|abstract[117]	new[116]|new[117]	_	_
18-12	2518-2528	inhibitory	place[116]|abstract[117]|substance[118]	new[116]|new[117]|new[118]	coref	18-22[121_118]
18-13	2529-2539	substances	place[116]|abstract[117]|substance[118]	new[116]|new[117]|new[118]	_	_
18-14	2540-2541	,	_	_	_	_
18-15	2542-2547	since	_	_	_	_
18-16	2548-2557	microbial	substance[119]	new[119]	coref	21-16[145_119]
18-17	2558-2568	aggregates	substance[119]	new[119]	_	_
18-18	2569-2576	protect	_	_	_	_
18-19	2577-2580	the	abstract[120]	giv[120]	_	_
18-20	2581-2595	microorganisms	abstract[120]	giv[120]	_	_
18-21	2596-2603	against	_	_	_	_
18-22	2604-2608	such	substance[121]	giv[121]	_	_
18-23	2609-2619	substances	substance[121]	giv[121]	_	_
18-24	2620-2622	as	_	_	_	_
18-25	2623-2627	they	place	giv	_	_
18-26	2628-2631	are	_	_	_	_
18-27	2632-2641	delivered	_	_	_	_
18-28	2642-2648	slowly	_	_	_	_
18-29	2649-2651	by	_	_	_	_
18-30	2652-2661	diffusion	abstract[123]	new[123]	_	_
18-31	2662-2666	from	abstract[123]	new[123]	_	_
18-32	2667-2670	the	abstract[123]|abstract[125]	new[123]|new[125]	coref	20-28[139_125]
18-33	2671-2677	liquid	abstract[123]|substance|abstract[125]	new[123]|new|new[125]	_	_
18-34	2678-2683	phase	abstract[123]|abstract[125]	new[123]|new[125]	_	_
18-35	2684-2685	.	_	_	_	_

#Text=The more sensitive organisms are in the deeper layers protected by layers of organisms embedded in an extracellular polymeric matrix .
19-1	2686-2689	The	animal[126]	new[126]	coref	19-14[129_126]
19-2	2690-2694	more	animal[126]	new[126]	_	_
19-3	2695-2704	sensitive	animal[126]	new[126]	_	_
19-4	2705-2714	organisms	animal[126]	new[126]	_	_
19-5	2715-2718	are	_	_	_	_
19-6	2719-2721	in	_	_	_	_
19-7	2722-2725	the	abstract[127]	new[127]	coref	19-12[128_127]
19-8	2726-2732	deeper	abstract[127]	new[127]	_	_
19-9	2733-2739	layers	abstract[127]	new[127]	_	_
19-10	2740-2749	protected	abstract[127]	new[127]	_	_
19-11	2750-2752	by	abstract[127]	new[127]	_	_
19-12	2753-2759	layers	abstract[127]|abstract[128]	new[127]|giv[128]	_	_
19-13	2760-2762	of	abstract[127]|abstract[128]	new[127]|giv[128]	_	_
19-14	2763-2772	organisms	abstract[127]|abstract[128]|animal[129]	new[127]|giv[128]|giv[129]	_	_
19-15	2773-2781	embedded	abstract[127]|abstract[128]|animal[129]	new[127]|giv[128]|giv[129]	_	_
19-16	2782-2784	in	abstract[127]|abstract[128]|animal[129]	new[127]|giv[128]|giv[129]	_	_
19-17	2785-2787	an	abstract[127]|abstract[128]|animal[129]|substance[130]	new[127]|giv[128]|giv[129]|new[130]	coref	21-11[144_130]
19-18	2788-2801	extracellular	abstract[127]|abstract[128]|animal[129]|substance[130]	new[127]|giv[128]|giv[129]|new[130]	_	_
19-19	2802-2811	polymeric	abstract[127]|abstract[128]|animal[129]|substance[130]	new[127]|giv[128]|giv[129]|new[130]	_	_
19-20	2812-2818	matrix	abstract[127]|abstract[128]|animal[129]|substance[130]	new[127]|giv[128]|giv[129]|new[130]	_	_
19-21	2819-2820	.	_	_	_	_

#Text=Adaptation to toxic chemicals can be slow and can go through the stages of survival , tolerance , capture , and — if at all biodegradable — the final adaptation stage is degradation .
20-1	2821-2831	Adaptation	abstract[131]	new[131]	coref	20-30[0_131]
20-2	2832-2834	to	abstract[131]	new[131]	_	_
20-3	2835-2840	toxic	abstract[131]|substance[132]	new[131]|new[132]	_	_
20-4	2841-2850	chemicals	abstract[131]|substance[132]	new[131]|new[132]	_	_
20-5	2851-2854	can	_	_	_	_
20-6	2855-2857	be	_	_	_	_
20-7	2858-2862	slow	_	_	_	_
20-8	2863-2866	and	_	_	_	_
20-9	2867-2870	can	_	_	_	_
20-10	2871-2873	go	_	_	_	_
20-11	2874-2881	through	_	_	_	_
20-12	2882-2885	the	abstract[133]	new[133]	_	_
20-13	2886-2892	stages	abstract[133]	new[133]	_	_
20-14	2893-2895	of	abstract[133]	new[133]	_	_
20-15	2896-2904	survival	abstract[133]|event	new[133]|new	_	_
20-16	2905-2906	,	abstract[133]	new[133]	_	_
20-17	2907-2916	tolerance	abstract[133]|abstract	new[133]|new	ana	20-25
20-18	2917-2918	,	abstract[133]	new[133]	_	_
20-19	2919-2926	capture	abstract[133]|event	new[133]|new	_	_
20-20	2927-2928	,	_	_	_	_
20-21	2929-2932	and	_	_	_	_
20-22	2933-2934	—	_	_	_	_
20-23	2935-2937	if	_	_	_	_
20-24	2938-2940	at	_	_	_	_
20-25	2941-2944	all	abstract	giv	_	_
20-26	2945-2958	biodegradable	_	_	_	_
20-27	2959-2960	—	_	_	_	_
20-28	2961-2964	the	abstract[139]	giv[139]	coref	20-33[0_139]
20-29	2965-2970	final	abstract[139]	giv[139]	_	_
20-30	2971-2981	adaptation	abstract|abstract[139]	giv|giv[139]	_	_
20-31	2982-2987	stage	abstract[139]	giv[139]	_	_
20-32	2988-2990	is	_	_	_	_
20-33	2991-3002	degradation	abstract	giv	coref	24-1[153_0]
20-34	3003-3004	.	_	_	_	_

#Text=The process can even remove non-biodegradable constituents by integration in the extracellular matrix to build more aggregates .
21-1	3005-3008	The	event[141]	giv[141]	coref	27-8[173_141]
21-2	3009-3016	process	event[141]	giv[141]	_	_
21-3	3017-3020	can	_	_	_	_
21-4	3021-3025	even	_	_	_	_
21-5	3026-3032	remove	_	_	_	_
21-6	3033-3050	non-biodegradable	substance[142]	giv[142]	_	_
21-7	3051-3063	constituents	substance[142]	giv[142]	_	_
21-8	3064-3066	by	_	_	_	_
21-9	3067-3078	integration	event[143]	new[143]	_	_
21-10	3079-3081	in	event[143]	new[143]	_	_
21-11	3082-3085	the	event[143]|substance[144]	new[143]|giv[144]	_	_
21-12	3086-3099	extracellular	event[143]|substance[144]	new[143]|giv[144]	_	_
21-13	3100-3106	matrix	event[143]|substance[144]	new[143]|giv[144]	_	_
21-14	3107-3109	to	_	_	_	_
21-15	3110-3115	build	_	_	_	_
21-16	3116-3120	more	substance[145]	giv[145]	_	_
21-17	3121-3131	aggregates	substance[145]	giv[145]	_	_
21-18	3132-3133	.	_	_	_	_

#Text=HyVAB® is a compact reactor that integrates both anaerobic and aerobic processes .
22-1	3134-3140	HyVAB®	abstract	giv	coref	22-3[147_0]
22-2	3141-3143	is	_	_	_	_
22-3	3144-3145	a	abstract[147]	giv[147]	coref	25-13[0_147]
22-4	3146-3153	compact	abstract[147]	giv[147]	_	_
22-5	3154-3161	reactor	abstract[147]	giv[147]	_	_
22-6	3162-3166	that	abstract[147]	giv[147]	_	_
22-7	3167-3177	integrates	abstract[147]	giv[147]	_	_
22-8	3178-3182	both	abstract[147]|abstract[148]	giv[147]|giv[148]	_	_
22-9	3183-3192	anaerobic	abstract[147]|abstract[148]	giv[147]|giv[148]	_	_
22-10	3193-3196	and	abstract[147]|abstract[148]	giv[147]|giv[148]	_	_
22-11	3197-3204	aerobic	abstract[147]|abstract[148]	giv[147]|giv[148]	_	_
22-12	3205-3214	processes	abstract[147]|abstract[148]	giv[147]|giv[148]	_	_
22-13	3215-3216	.	_	_	_	_

#Text=Wastewater is introduced at the bottom
23-1	3217-3227	Wastewater	substance	giv	coref	29-8
23-2	3228-3230	is	_	_	_	_
23-3	3231-3241	introduced	_	_	_	_
23-4	3242-3244	at	_	_	_	_
23-5	3245-3248	the	place[150]	new[150]	_	_
23-6	3249-3255	bottom	place[150]	new[150]	_	_

#Text=anaerobic digestion ( AD ) stage , where organic matter is degraded and converted into methane .
24-1	3256-3265	anaerobic	event[151]|abstract[153]	new[151]|giv[153]	coref	25-11[159_153]
24-2	3266-3275	digestion	event[151]|abstract[153]	new[151]|giv[153]	_	_
24-3	3276-3277	(	abstract[153]	giv[153]	_	_
24-4	3278-3280	AD	abstract|abstract[153]	new|giv[153]	coref	28-13
24-5	3281-3282	)	abstract[153]	giv[153]	_	_
24-6	3283-3288	stage	abstract[153]	giv[153]	_	_
24-7	3289-3290	,	abstract[153]	giv[153]	_	_
24-8	3291-3296	where	abstract[153]	giv[153]	_	_
24-9	3297-3304	organic	abstract[153]|substance[154]	giv[153]|new[154]	_	_
24-10	3305-3311	matter	abstract[153]|substance[154]	giv[153]|new[154]	_	_
24-11	3312-3314	is	abstract[153]	giv[153]	_	_
24-12	3315-3323	degraded	abstract[153]	giv[153]	_	_
24-13	3324-3327	and	abstract[153]	giv[153]	_	_
24-14	3328-3337	converted	abstract[153]	giv[153]	_	_
24-15	3338-3342	into	_	_	_	_
24-16	3343-3350	methane	substance	new	_	_
24-17	3351-3352	.	_	_	_	_

#Text=The remaining unconsumed organics flow up for further treatment in the aerobic biofilm stage designed as a Continuous Flow Intermittent Cleaning ( CFIC® ) .
25-1	3353-3356	The	substance[156]	new[156]	_	_
25-2	3357-3366	remaining	substance[156]	new[156]	_	_
25-3	3367-3377	unconsumed	substance[156]	new[156]	_	_
25-4	3378-3386	organics	substance[156]	new[156]	_	_
25-5	3387-3391	flow	_	_	_	_
25-6	3392-3394	up	_	_	_	_
25-7	3395-3398	for	_	_	_	_
25-8	3399-3406	further	abstract[157]	giv[157]	_	_
25-9	3407-3416	treatment	abstract[157]	giv[157]	_	_
25-10	3417-3419	in	_	_	_	_
25-11	3420-3423	the	abstract[159]	giv[159]	coref	26-9[167_159]
25-12	3424-3431	aerobic	abstract[159]	giv[159]	_	_
25-13	3432-3439	biofilm	abstract|abstract[159]	giv|giv[159]	coref	26-6
25-14	3440-3445	stage	abstract[159]	giv[159]	_	_
25-15	3446-3454	designed	abstract[159]	giv[159]	_	_
25-16	3455-3457	as	abstract[159]	giv[159]	_	_
25-17	3458-3459	a	abstract[159]|abstract[161]	giv[159]|new[161]	appos	25-23[0_161]
25-18	3460-3470	Continuous	abstract[159]|abstract[160]|abstract[161]	giv[159]|new[160]|new[161]	_	_
25-19	3471-3475	Flow	abstract[159]|abstract[160]|abstract[161]	giv[159]|new[160]|new[161]	_	_
25-20	3476-3488	Intermittent	abstract[159]|abstract[161]	giv[159]|new[161]	_	_
25-21	3489-3497	Cleaning	abstract[159]|abstract[161]	giv[159]|new[161]	_	_
25-22	3498-3499	(	_	_	_	_
25-23	3500-3505	CFIC®	abstract	giv	coref	27-13[174_0]
25-24	3506-3507	)	_	_	_	_
25-25	3508-3509	.	_	_	_	_

#Text=Plastic bio-carriers serve as a biofilm substratum in the aerobic biofilm stage , protecting the biofilm from shear force .
26-1	3510-3517	Plastic	substance[163]	new[163]	_	_
26-2	3518-3530	bio-carriers	substance[163]	new[163]	_	_
26-3	3531-3536	serve	_	_	_	_
26-4	3537-3539	as	_	_	_	_
26-5	3540-3541	a	object[165]	new[165]	_	_
26-6	3542-3549	biofilm	abstract|object[165]	giv|new[165]	coref	26-11
26-7	3550-3560	substratum	object[165]	new[165]	_	_
26-8	3561-3563	in	_	_	_	_
26-9	3564-3567	the	abstract[167]	giv[167]	coref	28-12[178_167]
26-10	3568-3575	aerobic	abstract[167]	giv[167]	_	_
26-11	3576-3583	biofilm	abstract|abstract[167]	giv|giv[167]	coref	26-15[168_0]
26-12	3584-3589	stage	abstract[167]	giv[167]	_	_
26-13	3590-3591	,	_	_	_	_
26-14	3592-3602	protecting	_	_	_	_
26-15	3603-3606	the	abstract[168]	giv[168]	coref	28-16[179_168]
26-16	3607-3614	biofilm	abstract[168]	giv[168]	_	_
26-17	3615-3619	from	_	_	_	_
26-18	3620-3625	shear	person|abstract[170]	new|new[170]	_	_
26-19	3626-3631	force	abstract[170]	new[170]	_	_
26-20	3632-3633	.	_	_	_	_

#Text=Excess aerobic sludge is washed off during the intermittent washing process ( i.e. , CFIC® ) .
27-1	3634-3640	Excess	substance[171]	new[171]	_	_
27-2	3641-3648	aerobic	substance[171]	new[171]	_	_
27-3	3649-3655	sludge	substance[171]	new[171]	_	_
27-4	3656-3658	is	_	_	_	_
27-5	3659-3665	washed	_	_	_	_
27-6	3666-3669	off	_	_	_	_
27-7	3670-3676	during	_	_	_	_
27-8	3677-3680	the	event[173]	giv[173]	_	_
27-9	3681-3693	intermittent	event[173]	giv[173]	_	_
27-10	3694-3701	washing	abstract|event[173]	new|giv[173]	_	_
27-11	3702-3709	process	event[173]	giv[173]	_	_
27-12	3710-3711	(	_	_	_	_
27-13	3712-3716	i.e.	abstract[174]	giv[174]	_	_
27-14	3717-3718	,	abstract[174]	giv[174]	_	_
27-15	3719-3724	CFIC®	abstract[174]	giv[174]	_	_
27-16	3725-3726	)	_	_	_	_
27-17	3727-3728	.	_	_	_	_

#Text=Part of the detached aerobic biofilm settles down by gravity to the AD stage in the HyVAB® , where it is degraded simultaneously with the feed substrates .
28-1	3729-3733	Part	_	_	_	_
28-2	3734-3736	of	_	_	_	_
28-3	3737-3740	the	substance[175]	new[175]	_	_
28-4	3741-3749	detached	substance[175]	new[175]	_	_
28-5	3750-3757	aerobic	substance[175]	new[175]	_	_
28-6	3758-3765	biofilm	substance[175]	new[175]	_	_
28-7	3766-3773	settles	_	_	_	_
28-8	3774-3778	down	_	_	_	_
28-9	3779-3781	by	_	_	_	_
28-10	3782-3789	gravity	abstract	new	_	_
28-11	3790-3792	to	_	_	_	_
28-12	3793-3796	the	abstract[178]	giv[178]	_	_
28-13	3797-3799	AD	abstract|abstract[178]	giv|giv[178]	_	_
28-14	3800-3805	stage	abstract[178]	giv[178]	_	_
28-15	3806-3808	in	abstract[178]	giv[178]	_	_
28-16	3809-3812	the	abstract[178]|abstract[179]	giv[178]|giv[179]	ana	28-20[0_179]
28-17	3813-3819	HyVAB®	abstract[178]|abstract[179]	giv[178]|giv[179]	_	_
28-18	3820-3821	,	_	_	_	_
28-19	3822-3827	where	_	_	_	_
28-20	3828-3830	it	abstract	giv	coref	29-25[190_0]
28-21	3831-3833	is	_	_	_	_
28-22	3834-3842	degraded	_	_	_	_
28-23	3843-3857	simultaneously	_	_	_	_
28-24	3858-3862	with	_	_	_	_
28-25	3863-3866	the	object[182]	new[182]	_	_
28-26	3867-3871	feed	substance|object[182]	new|new[182]	_	_
28-27	3872-3882	substrates	object[182]	new[182]	_	_
28-28	3883-3884	.	_	_	_	_

#Text=In this study , two types of wastewater — wastewater I ( WWI ) and wastewater II ( WWII ) — were fed to the reactor , and performance was evaluated on the basis of metformin reduction , chemical oxygen demand ( COD ) removal efficiency , and biogas production .
29-1	3885-3887	In	_	_	_	_
29-2	3888-3892	this	abstract[183]	giv[183]	_	_
29-3	3893-3898	study	abstract[183]	giv[183]	_	_
29-4	3899-3900	,	_	_	_	_
29-5	3901-3904	two	place[184]	new[184]	_	_
29-6	3905-3910	types	place[184]	new[184]	_	_
29-7	3911-3913	of	place[184]	new[184]	_	_
29-8	3914-3924	wastewater	place[184]|substance	new[184]|giv	appos	29-10[186_0]
29-9	3925-3926	—	_	_	_	_
29-10	3927-3937	wastewater	substance[186]|substance[187]	giv[186]|giv[187]	appos|appos	29-10[187_186]|29-16[188_187]
29-11	3938-3939	I	substance[186]|substance[187]	giv[186]|giv[187]	_	_
29-12	3940-3941	(	substance[187]	giv[187]	_	_
29-13	3942-3945	WWI	substance[187]	giv[187]	_	_
29-14	3946-3947	)	substance[187]	giv[187]	_	_
29-15	3948-3951	and	substance[187]	giv[187]	_	_
29-16	3952-3962	wastewater	substance[187]|substance[188]	giv[187]|giv[188]	_	_
29-17	3963-3965	II	substance[187]|substance[188]	giv[187]|giv[188]	_	_
29-18	3966-3967	(	substance[187]|substance[188]	giv[187]|giv[188]	_	_
29-19	3968-3972	WWII	substance[187]|substance[188]|event	giv[187]|giv[188]|new	_	_
29-20	3973-3974	)	substance[187]|substance[188]	giv[187]|giv[188]	_	_
29-21	3975-3976	—	_	_	_	_
29-22	3977-3981	were	_	_	_	_
29-23	3982-3985	fed	_	_	_	_
29-24	3986-3988	to	_	_	_	_
29-25	3989-3992	the	abstract[190]	giv[190]	_	_
29-26	3993-4000	reactor	abstract[190]	giv[190]	_	_
29-27	4001-4002	,	_	_	_	_
29-28	4003-4006	and	_	_	_	_
29-29	4007-4018	performance	abstract	new	_	_
29-30	4019-4022	was	_	_	_	_
29-31	4023-4032	evaluated	_	_	_	_
29-32	4033-4035	on	_	_	_	_
29-33	4036-4039	the	abstract[192]	new[192]	_	_
29-34	4040-4045	basis	abstract[192]	new[192]	_	_
29-35	4046-4048	of	abstract[192]	new[192]	_	_
29-36	4049-4058	metformin	abstract[192]|substance|abstract[194]	new[192]|giv|new[194]	_	_
29-37	4059-4068	reduction	abstract[192]|abstract[194]	new[192]|new[194]	_	_
29-38	4069-4070	,	abstract[192]	new[192]	_	_
29-39	4071-4079	chemical	abstract[192]|abstract[196]|abstract[199]	new[192]|new[196]|new[199]	_	_
29-40	4080-4086	oxygen	abstract[192]|substance|abstract[196]|abstract[199]	new[192]|new|new[196]|new[199]	_	_
29-41	4087-4093	demand	abstract[192]|abstract[196]|abstract[199]	new[192]|new[196]|new[199]	_	_
29-42	4094-4095	(	abstract[192]|abstract[199]	new[192]|new[199]	_	_
29-43	4096-4099	COD	abstract[192]|substance|abstract[199]	new[192]|new|new[199]	_	_
29-44	4100-4101	)	abstract[192]|abstract[199]	new[192]|new[199]	_	_
29-45	4102-4109	removal	abstract[192]|event|abstract[199]	new[192]|giv|new[199]	_	_
29-46	4110-4120	efficiency	abstract[192]|abstract[199]	new[192]|new[199]	_	_
29-47	4121-4122	,	abstract[192]	new[192]	_	_
29-48	4123-4126	and	abstract[192]	new[192]	_	_
29-49	4127-4133	biogas	abstract[192]|substance|abstract[201]	new[192]|new|new[201]	_	_
29-50	4134-4144	production	abstract[192]|abstract[201]	new[192]|new[201]	_	_
29-51	4145-4146	.	_	_	_	_
